EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1108-1112 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1108 - 1112
Section II - La réalité clinique
DOI https://doi.org/10.1051/medsci/200925121108
Published online 15 December 2009
  1. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312 : 724–9. [Google Scholar]
  2. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1. Purification of two immunoogically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985; 162 : 1208–22. [Google Scholar]
  3. Henderson B, Pettifer ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989; 75 : 306–10. [Google Scholar]
  4. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36 : 1681–90. [Google Scholar]
  5. Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmunity 2008; 31 : 219–27. [Google Scholar]
  6. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223 : 7–19. [Google Scholar]
  7. Brennan F, Mc Innes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118 : 3537–45. [Google Scholar]
  8. Boissier MC, Assier E, Falgarone G, et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008; 75 : 373–5. [Google Scholar]
  9. Scheinecker C, Redlich K, Smolen J. Cytokines as therapeutic targets: advances and limitations. Immunity 2008; 28 : 440–4. [Google Scholar]
  10. Launois R, Payet S, Saidenberg-Kermanac’h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 75 : 688–95. [Google Scholar]
  11. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis 2009 (sous presse). [Google Scholar]
  12. Ranganathan P. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Curr Opin Mol Ther 2008; 10 : 562–7. [Google Scholar]
  13. Delavallée L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008; 67 : 1332–8. [Google Scholar]
  14. Gallois A, Mazzorana M, Vacher J, Jurdic P. Ostéo-immunologie : une vision globale et intégrée du tissu squelettique et du sytème immunitaire. Med Sci (Paris) 2009; 25 : 259–65. [Google Scholar]
  15. Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : Une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008; 24 : 306–13. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.